Market Spotlight: Uterine Cancer
Market Spotlight: Uterine Cancer
$1,318.00
This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by 2028.
- In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by 2028.
- GlaxoSmithKline’s Jemperli, Merck & Co’s Keytruda, and Eisai’s Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes.
- The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in Phase III.
- Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the uterine cancer space comprise topline Phase III trial results for Xpovio and Jemperli, and expected CHMP supplemental opinions for Lenvima and Keytruda.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.4%. Drugs, on average, take 9.7 years from Phase I to approval in solid tumors, as well as in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I–II, and only 5% in Phase III–IV.
- The US has a substantial lead in the number of uterine neoplasms clinical trials globally. Spain leads the major European markets, while China, South Korea, and Thailand share the top spot in Asia.
- Clinical trial activity in the uterine neoplasms space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.
- AstraZeneca and Sanofi lead the industry sponsors with the highest overall number of clinical trials for uterine neoplasms.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Chemotherapy
10 Hormone therapy
10 Immunotherapy
10 Palliative care
11 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 Multiple Drugs for Uterine Cancer (March 19, 2021)
24 Bavencio for Uterine Cancer (May 30, 2020)
26 Trodelvy for Uterine Cancer (May 13, 2020)
28 DKN-01 for Uterine Cancer (April 23, 2020)
31 KEY UPCOMING EVENTS
32 KEY REGULATORY EVENTS
32 Keeping Track: Merck & Co. In Spotlight With Keytruda Approval
32 Jemperli Approval Makes Everyone Happy
32 Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?
33 GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
34 PROBABILITY OF SUCCESS
35 LICENSING AND ASSET ACQUISITION DEALS
35 BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC
36 REVENUE OPPORTUNITY
37 CLINICAL TRIAL LANDSCAPE
38 Sponsors by status
39 Sponsors by phase
40 Recent events
42 BIBLIOGRAPHY
43 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of uterine cancer, 2019–28
17 Figure 2: Overview of pipeline drugs for uterine cancer in the US
17 Figure 3: Pipeline drugs for uterine cancer, by company
18 Figure 4: Pipeline drugs for uterine cancer, by drug type
18 Figure 5: Pipeline drugs for uterine cancer, by classification
24 Figure 6: Multiple Drugs for Uterine Cancer (March 19, 2021): Phase III – KEYNOTE-775 (w/Pembrolizumab)
26 Figure 7: Bavencio for Uterine Cancer (May 30, 2020): Phase II – TROPHIMMUN (Gestational Trophoblastic Neoplasias (GTN))
28 Figure 8: Trodelvy for Uterine Cancer (May 13, 2020): Phase I/II – Epithelial Cancer
30 Figure 9: DKN-01 for Uterine Cancer (April 23, 2020): Phase II – Gynecologic Malignancies (P204)
31 Figure 10: Key upcoming events in uterine cancer
34 Figure 11: Probability of success in the solid tumors pipeline
37 Figure 12: Clinical trials in uterine cancer
37 Figure 13: Top 10 drugs for clinical trials in uterine cancer
38 Figure 14: Top 10 companies for clinical trials in uterine cancer
38 Figure 15: Trial locations in uterine cancer
39 Figure 16: Uterine cancer trials status
40 Figure 17: Uterine cancer trials sponsors by phase
LIST OF TABLES
12 Table 1: Incident cases of uterine cancer, 2019–28
14 Table 2: Five-year prevalent cases of uterine cancer, 2019–28
16 Table 3: Marketed drugs for uterine cancer
19 Table 4: Pipeline drugs for uterine cancer in the US
23 Table 5: Multiple Drugs for Uterine Cancer (March 19, 2021)
25 Table 6: Bavencio for Uterine Cancer (May 30, 2020)
27 Table 7: Trodelvy for Uterine Cancer (May 13, 2020)
29 Table 8: DKN-01 for Uterine Cancer (April 23, 2020)
36 Table 9: Historical global sales, by drug ($m), 2016–20
36 Table 10: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP) 
Sign up to the